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Ultrasound (US)-guided breast biopsy has become the main method for diagnosing breast 
pathology, and it has a high diagnostic accuracy, approaching that of open surgical biopsy. 
However, methods for confirming adequate lesion retrieval after US-guided biopsy are relatively 
limited and false-negative results are unavoidable. Determining imaging-pathology concordance 
after US-guided biopsy is essential for validating the biopsy result and providing appropriate 
management. In this review article, we briefly present the results of US-guided breast biopsy; 
describe general aspects to consider when establishing imaging-pathology concordance; and 
review the various categories of imaging-pathology correlations and corresponding management 
strategies. 
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Introduction
Percutaneous breast biopsy has become the foundation of diagnosing breast pathology, with most 
biopsies performed under imaging guidance [1]. With technological advancements in both imaging 
techniques and larger core biopsy devices, ultrasound (US)-guided biopsy is now widely applied to the 
majority of breast lesions, including microcalcifications and non-mass lesions [2-4]. The false-negative 
rate of 14-gauge US-guided core needle biopsy (CNB) ranges from 0.1% to 3.7%, which approaches 
that of open surgical biopsy [1,5-11]. However, the success of an imaging-guided breast biopsy 
depends not only on the biopsy technique, but also on determining imaging-pathology concordance and 
appropriate post-biopsy management for patients after the procedure. In this article, we briefly review 
the published results of US-guided breast biopsy, discuss aspects to consider when establishing imaging-
pathology concordance, describe the possible categories of imaging-pathology correlations, and briefly 
discuss the appropriate post-biopsy management for each category, along with selected images. 
Review of US-Guided Breast Biopsy
US-guided CNB has shown high diagnostic accuracy for the diagnosis of breast cancer. Although 
first described by Roberts et al. in 1975 [12], it became widely used to evaluate breast lesions after 
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Parker et al. first reported the use of US-guided 14-gauge CNB in 
1993 [1,13]. Their initial results reported 100% agreement between 
needle-core and surgical diagnoses in 49 excised lesions, including 
34 cancers [13]. A later study in 2005 with long-term follow-up 
reported a false-negative rate of 3.7% for 14-gauge US-guided 
CNB, with three delayed diagnoses of cancer occurring at the site of 
prior CNB [5]. However, recent studies published in the last decade 
have reported slightly lower false-negative rates of US-guided CNB, 
ranging from 0.1% to 2.5%, with most cases identified because of 
discordance between imaging results and CNB histologic findings 
(Table 1) [7-11,14,15]. The reported underestimation rate of high-
risk lesions through US-guided CNB, a category primarily composed 
of atypical ductal hyperplasia (ADH) lesions in most studies, ranges 
from 24.5% to 65% [7,8,10,16]. 
In the last decade, US-guided vacuum-assisted breast biopsy 
(VABB) has become widely practiced for both diagnostic and 
therapeutic purposes [17]. The reported false-negative rates for 
11-gauge or 8-gauge US-guided VABB are approximately 0.1%-1%, 
and the underestimation rate of high-risk lesions is approximately 
0%-20% [18-21]. One or two missed cancers were reported in 
several studies on 11-gauge US-guided VABB, all of which were 
considered imaging-pathology discordant [18,22,23]. In one 
study, a false-negative result underwent repeat biopsy due to the 
progression of suspicious imaging findings [21]. In a recent study 
analyzing results from a 10-year period of US-guided VABB, the 
two false-negative results were cases performed for suspicious 
microcalcifications in which specimen mammography showed 
insufficient calcification; as such, these cases were considered 
imaging-pathology discordant [20]. 
Therefore, radiologists performing US-guided breast biopsy should 
be aware of the possibility of a false-negative diagnosis and be 
familiar with not only the biopsy technique, but how to determine 
imaging-pathology concordance, as well as the appropriate 
management strategies for patients after the procedure. In order 
to appropriately determine imaging-pathology concordance, it 
is crucial to be familiar with the Breast Imaging Reporting and 
Data System (BI-RADS) lexicon and classification for all available 
imaging modalities. In the following section, we will discuss several 
general aspects to consider when establishing imaging-pathology 
concordance after US-guided breast biopsy. 
Aspects to Consider When Establishing 
Imaging-Pathology Concordance after 
US-Guided Breast Biopsy
Adequate Targeting 
Although US-guided breast biopsy has an advantage over stere-
otactic biopsy in that targeting of the lesion can be monitored by 
Table 1. Summary of false-negative results of ultrasound-guided 14-gauge core needle biopsy
Author
Year of 
publication
Patient inclusion 
years
No. of lesions
False-negative 
rate
Characteristics of 
false-negative results
Underestimation rate of 
high-risk lesions
Schueller et al. [8] 2008 1995-2005 1,352 11/699 (1.6) Imaging-pathology discordance 
(n=11)
27/86 (31.4)
Youk et al. [10] 2008 2000-2005 2,420 31/1,312 (2.4) Imaging-pathology discordance 
(n=21)
25/93 (27)
Palpable mass (n=3)
Nipple discharge (n=1)
Progression at ultrasonography 
follow-up (n=6)
Youk et al. [9] 2010 2000-2007 3,724 50/1,982 (2.5) Imaging-pathology discordance 
(n=34)
41/127 (32.3)
Palpable mass (n=12)
Nipple discharge (n=1)
Progression at ultrasonography 
follow-up (n=3)
Zhang et al. [11] 2012 2005-2011 1,388 2/1,388 (0.1) Imaging-pathology discordance 
(n=2)
N/A
Jung et al. [14] 2017 2005-2012 9,068 63/3,067 (2.0) Imaging-pathology discordance 
(n=58)
79/322 (24.5)
Progression at ultrasonography 
follow-up (n=5)
N/A, not available.
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real-time needle visualization, the methods for confirming adequate 
tissue sampling are relatively limited. Specimen mammography 
cannot be applied as a confirmation method for tissue retrieval from 
breast lesions without suspicious microcalcifications, and therefore 
real-time evaluation of the needle position is very important. The 
radiologist must be aware of any technical difficulties that can cause 
targeting errors secondary to poor needle or lesion visualization, 
deep lesions, mobile lesions, or dense tissue that is difficult to 
traverse [24]. During the procedure, obtaining post-fire needle 
position verification by obtaining US images that show the entire 
length of the needle passing through the target lesion are important 
for assuring that adequate targeting was achieved (Fig. 1). For small 
lesions, US images may appear as if the needle is within a lesion 
when it is actually adjacent to the lesion, and additionally obtaining 
post-fire images in the orthogonal plane can help evaluate the 
needle position more precisely [25]. 
A B
Fig. 1. A 73-year-old woman with known breast cancer who underwent targeted ultrasonography (US) for an additional suspicious 
lesion on breast magnetic resonance (MR) imaging.
A. Axial early dynamic contrast-enhanced MR shows segmental non-mass enhancement (arrow) in the right outer central breast. B. Targeted 
US shows segmental ductal dilatation with an isoechoic intraductal lesion (arrow) in the right outer central breast, correlated with the non-
mass enhancement on MR images. C, D. Pre- (C) and post-fire US (D) during US-guided core needle biopsy (CNB) show that the needle 
passed through the subcutaneous fat layer anterior to the target (arrow), failing to sample the right outer central breast lesion. The CNB 
result was fibroadipose tissue, and the final surgical pathological result following US-guided localization was intraductal papilloma. 
C D
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Adequate Sampling
Although image-guided percutaneous breast biopsies are an 
accurate alternative to excisional biopsy, sampling error is a major 
possible limitation and can result in a false-negative diagnosis or 
histologic underestimation. In a validation study of 1,352 14-gauge 
US-guided CNB cases, in all 11 false-negative cases, the most 
suspicious areas of each lesion were missed by the needle, and 
the lesions were considered imaging-pathology discordant [8]. It 
is important to be familiar with the BI-RADS classification for all 
available imaging modalities, and to sample the most suspicious 
area seen on imaging (Fig. 2). The number and quality of specimens 
have also been associated with a reliable histological diagnosis. 
Studies have shown that a minimum of four to five cores are 
necessary to obtain a definitive diagnosis with US-guided CNB, but 
lesions with calcifications may require more samples [6,8,23,25,26]. 
An intact specimen that has >1 cm of uninterrupted length and 
sinks to the bottom when put into saline suggests adequate 
sampling and is correlated with diagnostic yield [25].  
US-guided breast biopsy can be performed for suspicious 
microcalcifications detected on US and has advantages over 
C
Fig. 2. A 42-year-old woman who was originally referred for 
excision of biopsy-proven intraductal papilloma.
A. Ultrasonography obtained at an outside institution shows a 
complex cystic and solid mass in the right upper central breast. 
The biopsy result was intraductal papilloma, and the patient was 
referred to our institution for surgical excision. B. Ultrasonography 
performed at our institution shows an irregular mass (arrow) at 
the same quadrant, with a surrounding non-mass lesion. C. Spot 
magnification view that was taken after placing a metallic skin 
marker at the suspicious mass shows that it correlated with a mass 
containing suspicious microcalcifications. The biopsy result of this 
area was ductal carcinoma in situ, and the final surgical pathological 
result was invasive ductal carcinoma. 
A B
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stereotactic biopsy, including improved patient comfort, no breast 
compression or ionizing radiation, real-time visualization of needle 
placement, shorter procedure time, and lower cost [2]. Placing a 
metallic marker on the skin over the target lesion and performing 
mammography prior to biopsy can ensure correlations between the 
microcalcifications seen on mammography and the lesion seen in US. 
Calcified lesions are the main cause for histologic underestimation 
and false-negative results in 14-gauge US-guided CNB, due to 
discontinuity and histologic heterogeneity [21]. US-guided VABB is 
more accurate than 14-gauge CNB for the evaluation of suspicious 
microcalcifications detected on US, and successful calcification retrieval 
has been reported to be more frequent for lesions associated with 
masses or ductal dilatation on US located at the anterior or middle 
portion of the breast, and to be related to lesion size, distribution, 
and level of suspicion based on mammography [2,27]. In addition, 
non-mass lesions on US have shown lower agreement between US-
guided CNB and the surgical histological diagnosis than mass lesions 
[28]. Therefore, US-guided VABB may be more appropriate than 
14-gauge CNB for the evaluation of suspicious microcalcifications 
or non-mass lesions seen on US [2,3]. When performing US-guided 
breast biopsy for microcalcifications, it is essential to obtain specimen 
mammography and ensure that the targeted microcalcifications are 
identified in the histologic specimen (Fig. 3). 
       
BI-RADS Final Assessment Category
Since the 2003 edition of the BI-RADS was published, the BI-RADS 
lexicon and classification have proven to be useful for predicting 
the likelihood of malignancy in sonographically assessed breast 
lesions [29-31]. Each BI-RADS assessment category indicates an 
anticipated likelihood of malignancy, which is based on a thorough 
evaluation of the imaging features. 
Category 3 (probably benign) is reserved for specific imaging 
A
B
Fig. 3. A 43-year-old woman with suspicious calcifications on mammography.
A. Ultrasonography shows an isoechoic non-mass lesion containing tiny hyperechoic foci in the left lower outer breast (arrows). A metallic 
skin marker was positioned on the skin overlying this area. B. Spot magnification view shows suspicious fine pleomorphic calcifications at the 
area of the metallic skin marker. C. Specimen mammogram obtained after 14-gauge ultrasound-guided core needle biopsy shows that only 
one faint microcalcification (arrow) was retrieved, suggesting poor tissue sampling. The biopsy result was atypical ductal hyperplasia, and the 
final surgical pathological result was invasive ductal carcinoma. 
C
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is subdivided into 4A, 4B, and 4C [32]. The guidance range of the 
likelihood of malignancy is >2% and ≤10% for category 4A, >10% 
and ≤50% for category 4B, and >50% and <95% for category 4C. 
Although the subcategorization of sonographic BI-RADS category 
4 has been reported to be useful in predicting the likelihood 
of malignancy, established objective criteria do not exist for 
subcategorization within category 4, and interobserver agreement 
has been shown to be poor [29,31,34-36]. Generally, for category 
4A lesions, a benign core biopsy result would be considered 
concordant. For category 4C lesions, a benign core biopsy result 
would more often be regarded as discordant, whereas a malignant 
core biopsy result would be considered concordant. For category 4B 
lesions, a thorough review of imaging features and close imaging-
pathology correlation is required. In the long term, periodically 
performing internal audits would allow each radiologist to assess 
his or her overall performance and ultimately aid in determining 
imaging-pathology concordance. 
Category 5 (highly suggestive of malignancy) carries a very high 
findings known to have a likelihood of malignancy >0% but ≤2%. 
Such lesions include solid masses with a circumscribed margin, 
oval shape, and parallel orientation; complicated cysts; and 
clustered microcysts [32]. The use of assessment category 3 for 
other sonographic findings can be considered only if the radiologist 
has personal experience suggesting a likelihood of malignancy 
within the defined (≤2%) probably benign range. Although the 
recommended management is imaging follow-up, biopsy can be 
performed in specific circumstances, such as patient or physician 
preference. For category 3 lesions, a benign biopsy result can be 
regarded as concordant. Malignant biopsy results are considered 
discordant, but the sonographic features should be reviewed for 
subtle suspicious imaging features that can be overlooked [33]. 
Category 4 (suspicious) covers a wide range of likelihood 
of malignancy, ranging from 2% to 95%. Thus, almost all 
recommendations for image-guided breast interventions come from 
assessments made using this category. Starting in the fourth edition 
of BI-RADS and maintained in its recent fifth edition, category 4 
A
Fig. 4. A 42-year-old woman with a mass in her left breast.
A. Ultrasonography shows a 2-cm oval circumscribed mass (arrow) 
in the left inner central breast, which was assessed as Breast 
Imaging Reporting and Data System category 3. B. Ultrasound-
guided 14-gauge core needle biopsy was performed at the request 
of the patient, and the needle passed through the center of the 
mass (arrow). The biopsy result was fibrocystic change. C. Three years 
later, the patient returned, complaining of a new lump at the same 
site. Ultrasonography shows that the mass (arrow) had grown and 
was approximately 4 cm in diameter. The surgical pathological result 
was fibroadenoma with pseudoangiomatous stromal hyperplasia. 
B C
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probability (≥95%) of malignancy, and any benign percutaneous 
tissue diagnosis should be considered discordant. 
Whether Pathology Results Can Explain Imaging Findings
In addition to the benignity or malignancy of biopsy results, 
another aspect to consider when establishing imaging-pathology 
concordance is whether the histologic results provide an acceptable 
explanation for the imaging findings. Cases with discordant 
pathology and imaging diagnoses can be classified as discordant, 
even if both imply a benign disease process [37]. According to 
the imaging and pathology findings, larger tissue sampling such 
as US-guided VABB or short-interval imaging follow-up can be 
considered. For instance, benign nonspecific biopsy results may be 
considered discordant if obtained from a discrete solid mass, even 
if the lesion was initially thought to be benign (BI-RADS category 
2, 3, or 4a) (Fig. 4). In contrast, benign nonspecific results, such as 
fibrocystic change, may be considered concordant if biopsied from 
a cystic lesion or focal dilated duct. Although the classifications of 
several diagnoses vary slightly across studies, specific diagnoses 
are those of a specific entity that can account for the lesion, and 
include fibroadenoma, papilloma, tubular adenoma, hematoma or 
inflammation, abscess, hamartoma, fat necrosis, lymph node, cyst, 
A
Fig. 5. A 53-year-old woman with a palpable mass in her left 
breast.
A. Mammography ( left, mediolateral oblique view; r ight, 
craniocaudal view) shows an irregular mass with distortion (arrows) 
corresponding to the area of palpability. B. Ultrasonography (left, 
transverse view; right, longitudinal view) shows an irregular, non-
parallel hypoechoic mass containing calcifications (arrows). The 
result of ultrasound-guided 14-gauge core needle biopsy was 
invasive ductal carcinoma, which was considered a concordant 
malignancy. 
B
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fibroma, pseudoangiomatous stromal hyperplasia, and so forth 
[38,39]. Benign nonspecific diagnoses include fibrocystic changes, 
apocrine metaplasia, fibrous mastopathy, duct hyperplasia, and 
stromal fibrosis [38]. 
Categories of Imaging-Pathology Concordance
Parikh and Tickman [40] first described five possible case scenarios 
of imaging-pathology correlation, which are described in detail in 
the following section. 
Concordant Malignancy 
In this category, a lesion that shows imaging features suspicious 
for malignancy (i.e., BI-RADS category 4 or 5) is diagnosed as a 
malignancy on percutaneous biopsy. A typical example would be 
a spiculated mass seen on US that is diagnosed as invasive ductal 
carcinoma (Fig. 5). Appropriate action should be taken without 
delay. The radiologist should communicate the results to the 
referring physician, and the patient should be informed of the results 
and referred to a surgeon or oncologist for prompt treatment. 
Discordant Malignancy 
A lesion that shows benign imaging features (i.e., BI-RADS category 
2 or 3) but is diagnosed as a malignancy on percutaneous biopsy 
falls into this category (Fig. 6). The management should be identical 
to that of concordant malignancy, without any delay. Malignant 
A
Fig. 6. A 58-year-old woman with a palpable mass in her right 
breast. 
A. Mammography (left, mediolateral view; right, craniocaudal view) 
shows no abnormality in the palpable right upper outer breast, 
where a metallic skin marker was placed. B. Ultrasonography (left, 
transverse view; right, longitudinal view) shows an oval, parallel, 
and circumscribed isoechoic palpable mass (arrows). The mass was 
classified as Breast Imaging Reporting and Data System category 3, 
but ultrasound-guided 14-gauge core needle biopsy was performed 
at the request of the patient. The biopsy result was invasive 
carcinoma with micropapillary features, which was considered a 
discordant malignancy. The final surgical pathological result was 
invasive micropapillary carcinoma. 
B
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breast lesions that usually manifest as well-circumscribed masses 
include triple-negative or high nuclear-grade invasive ductal 
carcinomas not otherwise specified, metastatic lesions, lymphoma, 
and special-type tumors such as papillary carcinoma, mucinous 
carcinoma, medullary carcinoma, and metaplastic carcinoma [41,42]. 
The radiologist should also alert the pathologist to review and 
confirm the diagnosis to ensure that no interpretative or clerical 
errors account for the discrepancy. The images of the lesion should 
be reviewed thoroughly for image quality, imaging characteristics, 
and any missed features that might have caused underestimation in 
assessment. 
Concordant Benign 
A lesion with imaging features initially thought to be benign or likely 
benign (i.e., BI-RADS category 2, 3, or 4A) that also demonstrates 
benign pathology on percutaneous biopsy falls into this category 
(Fig. 7) [33]. Benign concordant results make up the majority of 
percutaneous breast biopsies [43,44]. Although this result can offer 
reassurance to both the physician and patient, follow-up imaging 
is necessary to confirm stability and to ensure the early detection 
of any possible missed cancers. However, the follow-up interval for 
benign biopsy findings with imaging-pathology concordance varies 
according to institution and is a matter of debate [45]. 
A common follow-up protocol is to perform short-interval follow-
up imaging at 6 months after biopsy, and then annually for at least 
24 months [46]. Others have suggested that follow-up intervals 
should be based on biopsy results, and recommend 6-month 
follow-up for nonspecific results and annual screening for specific 
benign diagnoses [47]. The reported percentage of missed cancers 
among concordant benign results using 14-gauge US-guided CNB 
ranges from 0% to 0.8% [5,8,9,48]. One study reported 3 delayed 
diagnoses of cancer at the site of prior CNB, which showed interval 
growth of 16, 23, and 27 months on follow-up US [5]. Another 
study reported 1 false-negative case diagnosed at a 6-month 
follow-up US because of interval growth [48]. In the last decade, a 
number of studies investigating the utility of short-interval follow-
up after benign concordant core needle breast biopsy results have 
been published. In one study, three missed cancers, all of which 
were palpable, among 1,492 lesions exhibited interval growth and 
were diagnosed at a 6-month follow-up [49]. In another study, two 
missed cancers among 1,147 lesions showed growth at a 6-month 
follow-up [38]. A review of the images revealed that one lesion was 
highly suspicious for malignancy and should had been regarded 
as imaging-pathology discordant, and that the other lesion had 
been biopsied for calcifications, but no calcifications were seen 
on the specimen radiograph. All other studies have reported that 
no malignancies were detected at the biopsy site during short-
interval follow-up [39,43,50-53]. Therefore, annual screening may 
be a reasonable follow-up protocol for benign concordant breast 
lesions assessed using US-guided CNB, provided that good imaging-
pathology correlation has been achieved. 
Discordant Benign 
A lesion in this category has imaging features suspicious for 
malignancy (i.e., BI-RADS category 4 or 5), but demonstrates benign 
pathology on percutaneous breast biopsy (Fig. 8). The reported 
percentages of imaging-pathology discordant lesions among breast 
CNB range from 2.0% to 19.2% [9,37,54-56]. Benign lesions 
with spiculated findings can mimic malignancy on US, including 
granular cell tumor, sclerosing adenosis, postsurgical scar, fat 
Fig. 7. A 24-year-old woman with a mass in her left breast. Ultrasonography (left, transverse view; right, longitudinal view) shows an 
oval circumscribed mass (arrows) in the palpable area of the left inner central breast. Ultrasound-guided 14-gauge core needle biopsy was 
performed at the request of the patient. The biopsy result was fibroadenoma, which was considered a concordant benign result. Subsequent 
vacuum-assisted biopsy also revealed fibroadenoma.
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necrosis, mastitis, diabetic mastopathy, and sarcoidosis [33,57,58]. 
However, approximately 4%-30.9% of discordant lesions after US-
guided CNB are confirmed as cancer by subsequent surgical excision 
[9,37,54-56]. If there is concern regarding a discordant benign core 
biopsy, it is prudent for the radiologist to immediately contact the 
interpreting pathologist and communicate about the discrepancy. 
Based on that discussion, the radiologist should communicate 
with the referring physician or patient and discuss the need for 
a repeat biopsy. In addition to surgical biopsy, US-guided VABB 
has been shown to be a valuable alternative to surgical biopsy 
for breast lesions with imaging-pathology discordance, and the 
reported upgrade rate ranges from 4.6% to 22.7% (Fig. 9) [54,59-
61]. Therefore, both surgical biopsy and US-guided VABB can be 
recommended for repeated biopsies of discordant benign lesions 
at US-guided CNB, and the best biopsy method should be chosen 
for each case through communication between the radiologist, 
pathologist, referring physician, and patient. 
Borderline or High-Risk 
This category refers to lesions that are not malignant but are 
considered to indicate an increased lifetime risk of developing 
breast cancer, including ADH, lobular neoplasia, radial scar, papillary 
lesions, and possible phyllodes tumors [40]. Controversy exists 
regarding the appropriate surgical and oncological treatment for 
these lesions. These issues are beyond the scope of this article, and 
other published articles focus on this issue [62,63]. For all breast 
A
Fig. 8. A 51-year-old woman with a palpable mass in her left 
breast.
A. Mammography (left, mediolateral view; right, craniocaudal view) 
shows a hyperdense mass (arrows) in the palpable area of the left 
outer central breast. B. Ultrasonography (left, transverse view; right, 
longitudinal view) shows an irregular hypoechoic mass (arrows) at 
the palpable site. The patient had previously undergone core needle 
biopsy at an outside hospital for the palpable mass, and the biopsy 
result was fibrocystic change. This was considered a discordant 
benign result. Repeat ultrasound-guided 14-gauge core needle 
biopsy was performed, revealing invasive ductal carcinoma. 
B
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lesions, as with 14-gauge US-guided CNB, determining imaging-
pathology concordance is pivotal when performing US-guided VABB 
for diagnostic purposes [17]. However, its importance tends to be 
less emphasized when performing therapeutic US-guided VABB 
aiming for complete image-guided excision. However, management 
options have become more diverse for borderline or high-risk lesions 
diagnosed following US-guided VABB with complete removal, and all 
characteristics, including the imaging findings, should be thoroughly 
reviewed to recommend appropriate management. These patients 
should be managed by a high-risk multidisciplinary team, with active 
discussion and collaboration across different subspecialties [64].  
Currently, active collaboration across multidisciplinary groups is 
making a significant difference in the management of patients with 
biopsy-proven high-risk lesions [64,65]. Most of the controversy 
regarding the management of such patients relates to the need 
for subsequent surgical excision. A thorough review and discussion 
of clinical and imaging findings, biopsy characteristics including 
the biopsy method and degree of removal, pathological findings 
including the extent of the lesion, and associations between clinical 
and pathological features and imaging can lead to personalized 
management recommendations [64,66]. For example, a diagnosis 
of focal ADH on pathology in a small lesion that has been nearly 
completely removed by vacuum-assisted biopsy may result in a 
recommendation of imaging follow-up [66]. In contrast, a finding 
of extensive high-risk disease in a lesion with limited sampling has 
a higher possibility of co-existing higher-grade lesions, and surgical 
A
Fig. 9. A 43-year-old woman with a palpable mass in her right 
breast. 
A. Transverse ultrasonography shows an irregular, non-parallel, 
spiculated mass (arrow) in the palpable right upper outer breast. The 
mass was classified as Breast Imaging Reporting and Data System 
category 4C. Ultrasound-guided 14-gauge core needle biopsy was 
performed, which obtained a pathological result of fibroadenoma 
with sclerosing adenosis. This was considered as a discordant 
benign result. B. Subsequent ultrasound-guided vacuum-assisted 
biopsy using a 9-gauge needle was performed, and the lesion was 
completely removed (left, ultrasonography during vacuum-assisted 
biopsy; right, ultrasonography immediately after completion of 
vacuum-assisted biopsy). The pathological result was sclerosing 
adenosis, and no newly developed lesions were observed at the 
biopsy site over a follow-up of more than 2 years. 
B
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excision may be recommended. Therefore, a single and unvarying 
approach does not seem appropriate for patients with biopsy-
proven high-risk breast lesions, and the management options can be 
individualized based on a multidisciplinary approach. 
Conclusion
US-guided breast biopsy is an accurate method for diagnosing 
breast cancer, with a false-negative rate ranging from 0.1% to 
2.5%. Determining imaging-pathology concordance after US-
guided breast biopsy is essential, as most false-negative cases are 
identified because of imaging-pathology discordance. The radiologist 
performing the biopsy should be aware of general aspects to 
consider when establishing imaging-pathology concordance and the 
possible categories of imaging-pathology correlations. Appropriate 
management, including active communication with the pathologist, 
referring physician, and patient, should be performed accordingly. 
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